In clinical aspects, both PAD4 inhibitor [49] and miR-155 [50] can suppress PAD4 activity and its mRNA expression, which can potentially act as a therapeutic tool in treating RA and other inflammatory diseases. This evidence concerns the gene PADI4 and rheumatoid arthritis.